Executive Summary
=================

1. Introduction
---------------

The mortality from cardiovascular disease (CVD) in renal allograft recipients is two to five times higher than in the general population. For haemodialysis patients this rate is even higher: The CVD-mortality is increased by five to 20 times. Apart from the classical risk factors, such as hypertension, diabetes mellitus, hyper- and dyslipidemia, these patients have elevated markers of oxidative stress like patients with end-stage renal diseases without renal replacement therapy.

In renal allograft recipients, oxidative stress is caused by the immunosuppressive therapy, for haemodialysis patients the dialysis itself produces reactive oxygen species (ROS), which lead to an imbalance of the antioxidative system.

Furthermore in all groups of patients renal insufficiency causes an overloading with urinary metabolites which together with a decreased number of erythrocytes results in an excess of ROS. Oxidative stress is causally involved in the pathogenesis of cardiovascular disease by damaging macromolecules such as lipids, proteins and the DNA. Antioxidative vitamins (vitamin A, C and E), which must be supplied with the food, reduce the production of reactive species and membrane lipid peroxidation in renal insufficiency patients and the general population as well. In the last years, a large number of studies including randomized controlled trials were conducted regarding a potential primary or secondary prevention effect in the general population. However, no metaanalysis of these studies yielded a beneficial or adverse effect of antioxidative vitamin supplementation on cardiovascular disease. Due to the high levels of oxidative stress in patients with chronic renal insufficiency, in patients with renal replacement therapy or with renal transplantation, this could be different. Therefore the purpose of this report is to analyse the effectiveness of antioxidative vitamins for the prevention of cardiovascular disease in these patients.

2. Objectives
-------------

To evaluate clinical effectiveness the following questions will be analysed:

Can the supplementation with antioxidative vitamins A, C or E in patients without a history of cardiovascular disease and who are renal transplant recipients or suffer from chronic renal insufficiency or from diabetic nephropathy, reduce the risk of cardiovascular morbidity and mortality (effectiveness in primary prevention)?Can the supplementation with antioxidative vitamins A, C or E in patients with a history of cardiovascular disease and who are renal transplant recipients or suffer from chronic renal insufficiency or from diabetic nephropathy, reduce the risk of cardiovascular morbidity and mortality (effectiveness in secondary prevention)?How large is the risk reduction and the proportion of prevented events, provided there is evidence for a beneficial effect of antioxidative vitamins in primary or secondary prevention?At what dosage and in which kind of application antioxidative vitamins either alone or in combination were effective in primary or secondary prevention, provided there is evidence for a beneficial effect?The level of oxidative stress is elevated in patients after renal transplantation, in patients with renal insufficiency or diabetic nephropathy and is regarded as a factor which increases cardiovascular risk. Can supplementation with antioxidative vitamins A, C or E reduce oxidative stress measured by biomarkers in these subgroups of patients?

The purpose of the economic evaluation is to systematically review economic aspects and the evidence for cost-effectiveness of supplementation with antioxidative vitamins for reduction of cardiovascular events. In particular, the following questions are examined:

What are the costs of a supplementation with antioxidative vitamins per patient?What are the incremental net costs for an intervention with antioxidative vitamins (costs of the intervention minus savings by avoided cardiovascular events) per event-free survival gained compared to no intervention? An event is defined as a cardiovascular event that is meaningful to patients or a combination of several cardiovascular events.

3. Clinical evaluation
----------------------

### 3.1 Methods

#### 3.1.1 Inclusion criteria for the evaluation of clinical effectiveness

All primary studies meeting the following criteria concerning study population, interventions and reference interventions, outcomes and study types were included:

Study population: Patients after renal transplantation, haemodialysis patients, not dialysis-requiring patients with chronic renal failure, patients with diabetic nephropathy. Both patients with and without history of cardiovascular disease shall be included.

Interventions and reference interventions: Vitamin A, C, E alone or combined with defined dosage and vitamin E-coated dialysers for haemodialysis patients. Either placebos or a dialyser without vitamin E-coating, whose biocompatibility is similar to the vitamin E-coated dialyser will be accepted as reference technologies.

Outcomes: clinical endpoints of cardiovascular disease with a minimum follow-up of six months, intermediate outcomes such as oxidative stress or preliminary stages of cardiovascular disease without any restriction to the length of the follow-up period.

Study types: randomized controlled clinical trials, not-randomized controlled intervention studies with parallel control groups, prospective observational studies with parallel control groups.

#### 3.1.2 Literature search

The literature search was performed in the electronic data bases of the DIMDI. The electronic searches covered the period from 1995 to 4^th^ of April 2005.

The search for HTA reports, systematic reviews and health-economic evaluations was conducted without a temporal limitation in the data bases of the Cochrane library CDSR, NHS CRD DARE, the internationally Agency for Health Technology Assessment NHS CRD HTA, the National Health Service in Great Britain NHS EED, the HTA database of the German Agency for Health Technology Assessment at the German Institute of Medical Documentation and Information and the IHTA data base.

#### 3.1.3 Selection, assessment and extraction of the literature

The inclusion and exclusion criteria defined above were used to pre-select articles screening titles and abstracts primarily thematically, and to order a full text version of articles that might meet the inclusion criteria. Whether they were included was decided independently by two co-workers. All selection steps are documented in form of reference lists at the DIMDI. The reasons for exclusion of articles ordered in a full text version are reported.

Standardized check lists were used to assess the quality of the included articles. Data were extracted using extraction tables and forms, which were developed before the evaluation.

#### 3.1.4 Synthesis of information

The included studies were arranged according to the type of intervention (oral vitamin supplementation or infusion and dialysis with vitamin E-coated dialyzer), described and their study quality was assessed. A qualitative synthesis of the information was shown in evidence tables.

### 3.2 Results

#### 3.2.1 Results of the literature search

The literature search of the DIMDI in the electronic data bases retrieved 1213 hits in case of the search strategy for the evaluation of clinical effectiveness and 624 hits in case of the search strategy for the economic evaluation. The literature search in the Cochrane data base and the HTA data bases retrieved 113 hits. 21 publications met the inclusion criteria for the evaluation of clinical effectiveness. No suitable study for the economic evaluation was identified. The effect of oral supplementation or infusion of antioxidative vitamins was investigated in seven studies. The effect of vitamin E-coated dialysers in haemodialysis patients was examined in twelve studies. Two publications were used for the information on the study design of one of the included randomized clinical trials.

#### 3.2.2 Antioxidative vitamins for primary prevention of clinical cardiovascular endpoints

Studies in populations without a history of cardiovascular disease examining clinical endpoints, such as cardiovascular morbidity or mortality could not be identified.

#### 3.2.3 Antioxidative vitamins for secondary prevention of clinical cardiovascular endpoints

Two randomized, placebo-controlled trials analysing this question could be identified. The SPACE study of Boaz et al. 2000 \[[@R1]\] reported a beneficial effect on the combined event rate of fatal and non-fatal myocardial infarction, stroke, peripheral vascular disease and unstable angina of orally given vitamin E of 800 IU per day in haemodialysis patients (n=196) after a median follow up of 1.4 years (519 days) in comparison to the placebo group (RR=0.46, 95%-KI: 0.27-0.78, p=0.014). The second publication addressing this question is a post-hoc analysis of the subgroup of patients with mild-to-moderate renal insufficiency of the HOPE study (n=993). Patients in the intervention arm received a daily dose of 400 IU vitamin E. No statistically significant and clinically relevant effect on the combined event rate of cardiac deaths, non-fatal myocardial infarction and stroke was observed after a median follow-up of 4.5 years.

The methodological quality of these studies was good. They were double blinded, randomized multi-center trials with concealed assignment of treatment and good quality of design and conduct of the study.

#### 3.2.4 The effect of anti-oxidative vitamins on intermediate outcomes

17 studies were identified, which examined either the effect of oral vitamin E- or vitamin C-supplementation, or intravenous vitamin C-infusion (six publications) or the effect of vitamin E-coated dialyzers (twelve publications, one of it in both categories) on biomarkers of oxidative stress or on risk factors for cardiovascular disease or on changes in vessel parameters.

In 16 of 17 studies with intermediate endpoints the supplementation with vitamins was associated with a change of one or several of the examined outcomes in the expected direction. This means that the concentrations of the markers for oxidative stress decreased in the Vitamin E group, the progression of aortic calcification (only one study) was reduced, the intimate media thickness decreased and the lipid profile improved.

For a majority of the studies stochastic uncertainty of the estimate was considered by using hypothesis tests only for pre-post comparisons within the study arms, but not for the more relevant comparison between intervention and control group.

The methodological quality of the 17 studies is very limited. Hence, the results probably are biased by a different distribution of known and unknown confounding factors in intervention and control group respectively. Due to bad planning and reporting quality of the studies, it can hardly be estimated whether representative samples of clinical populations were examined.

### 3.3 Discussion

Only two studies could be identified analysing clinical endpoints of cardiovascular disease meaningful to patients. Both studies reported different results. The different results may be due to study populations with different risk profiles, to different dosage during the intervention or to variation by chance.

Due to the research results of the last ten years it can be assumed as sufficiently confirmed that for study populations with a history of cardiovascular disease and without or only a small proportion of patients with chronic kidney diseases vitamin E-supplementation do not show beneficial effects. This does not apply to patients with chronic renal failure.

Due to the absence of clinically meaningful endpoints, the relevance of studies analysing the effect of antioxidative vitamins on intermediate endpoints like oxidative stress markers is basically limited to show single intermediate steps of the postulated biological effect mechanisms by which a potentially beneficial effect could possibly be mediated. In 17 studies with intermediate endpoints supplementation with vitamins was associated with a change of one or several of the examined endpoints in the expected direction, such as a decrease in concentrations of biomarkers for oxidative stress, an improvement of the lipid profile, a reduced progression of aortic calcification or decrease of intimate media thickness. According to the unsatisfactory planning and reporting quality of these studies, it cannot be excluded that the reported effect estimators are biased by differences between intervention and control group.

4. Economic evaluation
----------------------

### 4.1 Methods

The same inclusion criteria for study population and type of intervention are applied for the economic evaluation. Outcomes however are limited to clinically meaningful endpoints. As types of economic evaluation were included: cost studies, cost-minimization analyses, cost-consequence analyses, cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses. Literature search and selection of the studies were performed analogous to clinical evaluation. Study quality was assessed using a standardized catalogue of criteria for health-economic evaluations. Data were extracted to standardized forms developed before evaluation.

### 4.2 Results

No health-economic study corresponding to the inclusion criteria was identified in the literature search. Hence, results about costs and cost-effectiveness of prevention of cardiovascular disease by antioxidative vitamins for patients after renal transplantation, haemodialysis patients or patients with chronic renal insufficiency are not available.

### 4.3 Discussion

The question of clinical effectiveness has to be clarified before the cost-effectiveness of primary or secondary prevention of cardiovascular disease by antioxidative vitamin supplementation can be examined.

5. Conclusion
-------------

The available evidence is not sufficient to support or to reject an effect of anti-oxidative vitamins on secondary prevention for cardiovascular disease for patients with chronic renal insufficiency or renal replacement therapy. There is a lack of randomized, placebo-controlled studies with a sufficient number of cases and clinical endpoints of cardiovascular disease, on the effect of antioxidative vitamins either orally applied or given by vitamin E-modified dialysers.

No data are available about supplementation with antioxidative vitamins for primary prevention of cardiovascular disease. Therefore the current evidence does not allow drawing conclusions concerning this subject either. For patients with a history of cardiovascular disease and without kidney diseases there is enough evidence to exclude a beneficial effect on secondary prevention of cardiovascular disease. For patients with chronic renal insufficiency and renal replacement therapy this question is still unsettled.
